The re-activation of GSK3β induced in CML cells by both celecoxib and rapamycin suggested that it might be the consequence of mTORC1 inhibition rather than its cause. The gene discussed is GSK3B; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.